Back to top
more

Axsome Therapeutics (AXSM)

(Delayed Data from NSDQ)

$90.07 USD

90.07
635,290

-0.63 (-0.69%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $90.16 +0.09 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Axsome (AXSM) Down 6.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.

Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?

by Zacks Equity Research

Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 5.95% and 6.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

TScan Therapeutics (TCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

by Zacks Equity Research

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

by Zacks Equity Research

Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.

Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

by Zacks Equity Research

Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.

Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal

by Zacks Equity Research

Data from a late-stage study shows that a five-week treatment with Axsome's (AXSM) experimental narcolepsy drug reduced weekly cataplexy attacks by 83%, compared to 66% for placebo.

Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

by Zacks Equity Research

Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.

Axsome (AXSM) Begins Dosing in Depression Study on Sunosi

by Zacks Equity Research

Axsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi (solriamfetol) for treating major depressive disorder. The stock rises 6%.

Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat

by Zacks Equity Research

Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 39.67% and 1.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Axsome (AXSM) Might Surprise This Earnings Season

by Zacks Equity Research

Axsome (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results

by Zacks Equity Research

Axsome (AXSM) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also provides regulatory updates on its pipeline candidates. Shares rise.

Axsome (AXSM) Surges 7.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition

by Zacks Equity Research

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.

Why Is Axsome (AXSM) Up 8.7% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates

by Zacks Equity Research

Axsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat estimates. The company's shares declined post earnings announcement.

Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.